Acknowledging and addressing real-world challenges to treating immune-related adverse events
Immune checkpoint inhibitors (ICIs) have revolutionized oncology treatment. However, their success is mitigated by the recognition that ICI-induced immune-related adverse events (irAEs) pose considerable challenges to patients and clinicians. These autoimmune toxicities are heterogeneous, unpredicta...
Saved in:
Main Authors: | Bonnie L Bermas, Mitchell S von Itzstein, David E Gerber, Alexa Meara |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/12/7/e009540.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Adverse events in the nervous system associated with blinatumomab: a real-world study
by: Wen Gao, et al.
Published: (2025-02-01) -
Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system
by: Ruichen Gao, et al.
Published: (2025-02-01) -
Adverse events following immunization surveillance on two types of enterovirus 71 vaccines: A real-world comparative study in China
by: Yiqing Zhu, et al.
Published: (2025-12-01) -
Endocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis
by: Meriç Dökmetaş, et al.
Published: (2025-01-01) -
A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system
by: Ke He, et al.
Published: (2025-01-01)